📣 VC round data is live. Check it out!

Harvard Bioscience Valuation Multiples

Discover revenue and EBITDA valuation multiples for Harvard Bioscience and similar public comparables like Biosynex, Finemedix, Nova Eye Medical, Modular Medical and more.

Harvard Bioscience Overview

About Harvard Bioscience

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.


Founded

2000

HQ

United States

Employees

355

Financials (LTM)

Revenue: $87M
EBITDA: $8M

EV

$62M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Harvard Bioscience Financials

Harvard Bioscience reported last 12-month revenue of $87M and EBITDA of $8M.

In the same LTM period, Harvard Bioscience generated $51M in gross profit, $8M in EBITDA, and had net loss of ($38M).

Revenue (LTM)


Harvard Bioscience P&L

In the most recent fiscal year, Harvard Bioscience reported revenue of $87M and EBITDA of $8M.

Harvard Bioscience is unprofitable as of last fiscal year, with gross margin of 58%, EBITDA margin of 9%, and net margin of (66%).

See analyst estimates for Harvard Bioscience
LTMLast FY202320242025202620272028
Revenue$87M$87M$112M$94M$87M
Gross Profit$51M$50M$66M$55M$50M
Gross Margin58%58%59%58%58%
EBITDA$8M$8M$8M($1M)($47M)
EBITDA Margin9%9%7%(1%)(54%)
EBIT Margin(13%)0%2%(7%)0%
Net Profit($38M)($57M)($3M)($12M)($57M)
Net Margin(43%)(66%)(3%)(13%)(66%)
Net Debt$27M

Financial data powered by Morningstar, Inc.

Harvard Bioscience Stock Performance

Harvard Bioscience has current market cap of $25M, and enterprise value of $62M.

Market Cap Evolution


Harvard Bioscience's stock price is $5.63.

Harvard Bioscience share price decreased by 12.6% in the last 30 days, and increased by 1105.6% in the last year.

Harvard Bioscience has an EPS (earnings per share) of $-12.57.

See more trading valuation data for Harvard Bioscience
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$62M$25M0.0%-12.6%-8.3%1105.6%$-12.57

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Harvard Bioscience Valuation Multiples

Harvard Bioscience trades at 0.7x EV/Revenue multiple, and 7.5x EV/EBITDA.

See NTM and 2027E valuation multiples for Harvard Bioscience

EV / Revenue (LTM)


Harvard Bioscience Financial Valuation Multiples

As of May 26, 2026, Harvard Bioscience has market cap of $25M and EV of $62M.

Harvard Bioscience has a P/E ratio of (0.7x).

LTMLast FY202320242025202620272028
EV/Revenue0.7x0.7x0.6x0.7x0.7x
EV/EBITDA7.5x7.7x7.8x(48.0x)(1.3x)
EV/EBIT(5.3x)n/m33.0x(10.0x)n/m
EV/Gross Profit1.2x1.3x0.9x1.1x1.3x
P/E(0.7x)(0.4x)(7.4x)(2.0x)(0.4x)
EV/FCF33.9x12.5x5.3x(34.2x)12.8x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Harvard Bioscience Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Harvard Bioscience Margins & Growth Rates

Harvard Bioscience grew revenue by 2% and EBITDA by 6% in the last fiscal year.

In the most recent fiscal year, Harvard Bioscience reported gross margin of 58%, EBITDA margin of 9%, and net margin of (66%).

See estimated margins and future growth rates for Harvard Bioscience

Harvard Bioscience Margins

Last FY202420252026202720282029
Gross Margin58%58%58%59%
EBITDA Margin9%(1%)(54%)10%
EBIT Margin0%(7%)0%3%
Net Margin(66%)(13%)(66%)(10%)
FCF Margin6%(2%)6%(3%)

Harvard Bioscience Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth2%(16%)(8%)2%
Gross Profit Growth5%(17%)(9%)5%
EBITDA Growth6%(116%)3482%(118%)
EBIT Growth2400%(428%)(102%)2400%
Net Profit Growth(84%)263%357%(84%)
FCF Growth(158%)(116%)(367%)(160%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Harvard Bioscience Operational KPIs

Harvard Bioscience's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Harvard Bioscience's Rule of 40 is 12% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Harvard Bioscience's Rule of X is 16% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Harvard Bioscience
LTMLast FY202320242025202620272028
Rule of 4013%12%
Bessemer Rule of X19%16%
Revenue per Employee$0.2M
Opex per Employee$0.1M
S&M Expenses to Revenue23%22%21%24%22%
G&A Expenses to Revenue21%20%20%23%20%
R&D Expenses to Revenue10%10%10%11%10%
Opex to Revenue58%57%65%58%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Harvard Bioscience Competitors

Harvard Bioscience competitors include Biosynex, Finemedix, Nova Eye Medical, Modular Medical, NanoRepro, Genematrix, IMD International Medical, Medclair, Pulsenmore and CS Diagnostics.

Most Harvard Bioscience public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Biosynex0.8x62.5x
Finemedix3.6x(23.2x)
Nova Eye Medical1.2x1.1x(6.9x)(14.4x)
Modular Medical(1.2x)
NanoRepro2.9x0.8x(4.0x)(12.0x)
Genematrix2.7x(24.7x)
IMD International Medical0.4x5.8x
Medclair4.2x21.4x

This data is available for Pro users. Sign up to see all Harvard Bioscience competitors and their valuation data.

Start Free Trial

Harvard Bioscience M&A Activity

Harvard Bioscience has acquired 4 companies to date.

Last acquisition by Harvard Bioscience was on January 22nd 2018. Harvard Bioscience acquired Data Sciences International for $70M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Harvard Bioscience

Data Sciences International
HEKA Elektronik
Triangle BioSystems
Multi Channel Systems
Description
Data Sciences International is a leader in wireless telemetry for physiologic monitoring in preclinical research. St. Paul, Minnesota-headquartered since 1977, DSI serves pharma giants like Pfizer and CROs with PONEMAH software and implants tracking cardiovascular, respiratory, and neurological signals in rodents and large animals.
HEKA Elektronik is a Lambrecht/Pfalz-based manufacturer of high-precision instrumentation and software for electrophysiology and industrial research. The company produces patch-clamp amplifiers like the EPC 10 series, multi-channel systems such as the EPC 805, and data acquisition tools including PATCHMASTER and Pulse software. These products support applications in neuroscience, cell biology, and ion channel studies. HEKA serves medical, pharmaceutical, and academic labs across Europe, North America, and Asia. Established in 1977, the firm maintains production facilities in Germany and distributes globally through regional offices.
Triangle BioSystems is a supplier of neural interfacing laboratory equipment tailored for scientific research. Durham, North Carolina-based, it customizes solutions by deeply understanding client workflows to outperform competitors in delivering optimal setups.
Multi Channel Systems is a Reutlingen-based company founded in 1996 that develops modular electrophysiology measurement systems including the ME16 amplifier and USB-probe for in vitro extracellular recordings used by universities and pharmaceutical researchers globally from its base in Germany's Science and Technology Park.
HQ CountryUnited StatesGermanyUnited StatesGermany
HQ City
Saint Paul, MN
Mannheim
Durham, NC
Reutlingen
Deal Date22 Jan 20188 Jan 20151 Oct 20141 Oct 2014
Valuation$70M$6M$2M$10M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Harvard Bioscience acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Harvard Bioscience

When was Harvard Bioscience founded?Harvard Bioscience was founded in 2000.
Where is Harvard Bioscience headquartered?Harvard Bioscience is headquartered in United States.
How many employees does Harvard Bioscience have?As of today, Harvard Bioscience has over 355 employees.
Who is the CEO of Harvard Bioscience?Harvard Bioscience's CEO is John D. Duke.
Is Harvard Bioscience publicly listed?Yes, Harvard Bioscience is a public company listed on Nasdaq.
What is the stock symbol of Harvard Bioscience?Harvard Bioscience trades under HBIO ticker.
When did Harvard Bioscience go public?Harvard Bioscience went public in 2000.
Who are competitors of Harvard Bioscience?Harvard Bioscience main competitors include Biosynex, Finemedix, Nova Eye Medical, Modular Medical, NanoRepro, Genematrix, IMD International Medical, Medclair, Pulsenmore, CS Diagnostics.
What is the current market cap of Harvard Bioscience?Harvard Bioscience's current market cap is $25M.
What is the current revenue of Harvard Bioscience?Harvard Bioscience's last 12 months revenue is $87M.
What is the current revenue growth of Harvard Bioscience?Harvard Bioscience revenue growth (NTM/LTM) is 4%.
What is the current EV/Revenue multiple of Harvard Bioscience?Current revenue multiple of Harvard Bioscience is 0.7x.
Is Harvard Bioscience profitable?Yes, Harvard Bioscience is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Harvard Bioscience?Harvard Bioscience's last 12 months EBITDA is $8M.
What is Harvard Bioscience's EBITDA margin?Harvard Bioscience's last 12 months EBITDA margin is 9%.
What is the current EV/EBITDA multiple of Harvard Bioscience?Current EBITDA multiple of Harvard Bioscience is 7.5x.
What is the current FCF of Harvard Bioscience?Harvard Bioscience's last 12 months FCF is $2M.
What is Harvard Bioscience's FCF margin?Harvard Bioscience's last 12 months FCF margin is 2%.
What is the current EV/FCF multiple of Harvard Bioscience?Current FCF multiple of Harvard Bioscience is 33.9x.
How many companies Harvard Bioscience has acquired to date?As of May 2026, Harvard Bioscience has acquired 4 companies.
What was the largest acquisition by Harvard Bioscience?$70M acquisition of Data Sciences International on 22nd January 2018 was the largest M&A Harvard Bioscience has done to date.
What companies Harvard Bioscience acquired?Harvard Bioscience acquired Data Sciences International, Multi Channel Systems, HEKA Elektronik, and Triangle BioSystems.
In how many companies Harvard Bioscience has invested to date?Harvard Bioscience hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Harvard Bioscience

Lists including Harvard Bioscience

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial